The HIB-202-101 study is a lupus nephritis clinical trial testing an investigational medication for adults with lupus nephritis. The goal is to assess the safety and tolerability of the study medication, felzartamab, as a potential treatment for lupus nephritis.
You may be eligible to join the study if you meet the following requirements*:
- 18 to 75 years old
- Confirmed diagnosis of Class 3 or 4 lupus nephritis (with or without Class 5)
- Lack of response to standard of care therapies for lupus nephritis
*Other study requirements will apply
See if you may qualifyParticipation in the HIB-202-101 study lasts about 1 year. If you choose to participate, you can expect the following steps:
1. Screening (1 month | May require more than one visit)
You will complete screening assessments at the study clinic to determine if you qualify for the study.
2. Study medication infusions (5 months | 9 visits)
You will receive 1 intravenous (IV) infusion of the study medication at each of the 9 study clinic visits. You will also receive premedication before infusions to help reduce the chance of a reaction.
3. Follow-up (7 months | 5 visits)
You will visit the study clinic regularly for continued study assessments to monitor how your body and the lupus nephritis respond to the study medication.
Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.
